O

Orion Oyj
OMXH:ORNBV

Watchlist Manager
Orion Oyj
OMXH:ORNBV
Watchlist
Price: 54.82 EUR 2.47%
Market Cap: 7.7B EUR

Orion Oyj
Investor Relations

Orion Oyj, a stalwart in the pharmaceutical industry, has carved out a significant niche for itself since its inception in Finland. The company was founded in 1917, and over the years, it has evolved into a crucial player in the global medical landscape. As a fully integrated pharmaceutical entity, Orion’s operations encompass everything from research and development to manufacturing and distribution. Its primary areas of focus include the development of therapies for central nervous system disorders, oncology, and respiratory diseases, as well as a selection of veterinary medicines and active pharmaceutical ingredients (APIs). This comprehensive approach enables Orion to maintain control over the entire drug production pipeline, ensuring quality and innovation are at the forefront of its mission.

Orion's business strategy revolves around a robust combination of proprietary innovations and strategic partnerships. The company invests heavily in R&D, dedicating a substantial portion of its revenue to discovering and developing new drugs. By doing so, it fortifies its product pipeline, ensuring a steady influx of new offerings that cater to unmet medical needs, fostering a competitive edge in the market. Additionally, Orion supplements its earnings through collaborations with other pharmaceutical giants, expanding its market reach and sharing resources to mitigate risks associated with the costly drug development process. Through this dual approach of in-house excellence and collaborative ventures, Orion Oyj effectively sustains its financial health, continually fueling its growth and ensuring it remains a formidable force in the international pharmaceutical arena.

Show more
Loading

Earnings Calls

2024 Q4
Feb 21, 2025
Show Transcript
Previous
Next
Alliant Energy Reports Strong Growth and Strategic Investments for 2025
2024 Q4
Feb 21, 2025

In 2024, Alliant Energy's ongoing earnings grew to $3.04 per share, reflecting a solid compounded annual growth rate exceeding 6% over the past decade. Contributing factors included effective tax benefits and reduced operating expenses, with a notable $30 million decrease in O&M costs. Milder winter temperatures affected earnings by $0.15 per share, a deterioration compared to $0.06 in 2023. Looking forward, the 2025 earnings guidance is set between $3.15 and $3.25 per share, aligning with the company's ambitious 5% to 7% growth target. Additionally, Alliant secured $3 billion in loan guarantees to finance clean energy projects, reinforcing its commitment to sustainable and economic growth.

Show Full Analysis

Management

Mr. Rene Lindell M.Sc., Ph.D.
Chief Financial Officer & Member of Group Executive Management Board
No Bio Available
Mr. Olli Huotari Ll.M.
Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management Board
No Bio Available
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)
Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board
No Bio Available
Prof. Outi Vaarala M.D., Ph.D.
Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board
No Bio Available
Mr. Juhani Kankaanpaa
Senior VP of Global Operations & Member of Executive Management Board
No Bio Available
Mr. Niclas Lindstedt EMBA, M.Sc.
Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board
No Bio Available
Mr. Hao Pan M.Sc.
Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board
No Bio Available
Ms. Julia Irene Macharey
Senior Vice President of People & Culture and Member of Management Board
No Bio Available
Mr. Tuukka Hirvonen M.Sc.(Soc.)
Investor Relations & Financial Communications Officer
No Bio Available
Ms. Terhi Ormio
Vice President of Communications
No Bio Available

Contacts

Address
ETELA-SUOMEN
Espoo
Orionintie 1A
Contacts
+358104261.0
www.orion.fi